DFTX vs LBRX
DFTX: Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism. LBRX: LB Pharmaceuticals is a late-stage biopharmaceutical firm developing LB-102, a novel benzamide candidate aimed at becoming a first-in-class treatment for schizophrenia and mood disorders in the U.S. market.
Side-by-side fundamentals
| Metric | DFTX | LBRX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $42.65 | $34.78 | |
| Market cap as of 2026-07-29 | $5.5B | $997M | |
| PEG as of 2026-07-29 | -0.12 | n/a | |
| ROE as of 2026-07-29 | -102.5% | -17.7% | LBRX higher |
| ROA as of 2026-07-29 | -70.7% | -16.9% | LBRX higher |
| Debt / equity as of 2026-07-29 | 0.15 | 0.00 | LBRX lower |
| Beta as of 2026-07-29 | 2.30 | 1.22 | |
| 1-year return as of 2026-07-27 close | +337.0% | n/a |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.